Cargando…

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness

Acute myeloid leukemia (AML), with an incidence increasing with age, is the most common acute leukemia in adults. Concurrent comorbidities, mild to severe organ dysfunctions, and low performance status (PS) are frequently found in older patients at the onset, conditioning treatment choice and crucia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmieri, Raffaele, Paterno, Giovangiacinto, De Bellis, Eleonora, Mercante, Lisa, Buzzatti, Elisa, Esposito, Fabiana, Del Principe, Maria Ilaria, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016986/ https://www.ncbi.nlm.nih.gov/pubmed/31906489 http://dx.doi.org/10.3390/cancers12010120

Ejemplares similares

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation
por: Palmieri, Raffaele, et al.
Publicado: (2023)

Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
por: Paterno, Giovangiacinto, et al.
Publicado: (2022)

In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
por: Buzzatti, Elisa, et al.
Publicado: (2022)

Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients
por: Guarnera, Luca, et al.
Publicado: (2023)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic
por: Guarnera, Luca, et al.
Publicado: (2023)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
por: Coppola, Andrea, et al.
Publicado: (2015)

Can Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone
por: Borsellino, Beatrice, et al.
Publicado: (2022)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023)

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage
por: Arriga, Roberto, et al.
Publicado: (2015)

Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia: a multicenter report from the Campus ALL Network
por: Del Principe, Maria Ilaria, et al.
Publicado: (2019)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy
por: Del Principe, Maria Ilaria, et al.
Publicado: (2014)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis
por: Falconi, Giulia, et al.
Publicado: (2022)

Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
por: Ottone, Tiziana, et al.
Publicado: (2022)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
por: Del Prete, Valentina, et al.
Publicado: (2023)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment
por: Sconocchia, Giuseppe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dm1qqtv3mh0qnvu065ssftptbd